



# United Therapeutics Corporation

## J.P. Morgan Healthcare Conference

JANUARY 12, 2026

# Safe Harbor Statement

**All statements in this presentation are made as of January 12, 2026.** We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise.

**Statements included in this presentation** that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our revenue growth expectations, the timing and success of our pipeline programs, our planned manufacturing and field force expansions, our organ manufacturing efforts, and similar statements concerning anticipated future events and expectations.

**We caution you** that these statements are not guarantees of future performance and are subject to numerous evolving risks and uncertainties that we may not be able to accurately predict or assess, including the risk factors that we describe in our Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q. Any of these factors could cause actual results to differ materially from the expectations we express or imply in this presentation.

**This presentation** and any related discussions or statements are intended to educate investors about our company. Sometimes that process includes reporting on the progress and results of clinical trials or other developments with respect to our products. This presentation and any related discussions or statements are not intended to promote our products, to suggest that our products are safe and effective for any use other than what is consistent with their FDA-approved labeling, or to provide all available information regarding the products, their risks, or related clinical trial results. Anyone seeking information regarding the use of one of our products should consult the full prescribing information for the product available on our website at [www.unither.com](http://www.unither.com).

MIROKIDNEY, MIROLIVER, MIROLIVERELAP, ORENITRAM, REMODULIN, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. UHEART, UKIDNEY, ULOBE, ULUNG, UTHYMKIDNEY, and REMUNITYPRO are trademarks of United Therapeutics Corporation and/or its subsidiaries. ADCIRCA is a registered trademark of Eli Lilly and Company.

UTHR: A Public Benefit Corporation



# United Therapeutics: A Growth Story Unlike Any Other in Biotech



**United  
Therapeutics**  
A PUBLIC BENEFIT CORPORATION




# Double-Digit Compound Growth Expected to Continue into Next Decade



1. CAGR = Compound Annual Growth Rate 2. Since Remodulin approval in 2002



# RemunityPro - State-of-the-Art PAH Delivery Devices



# Advanced Therapeutics Addressing Rare Disease



**orenitram<sup>®</sup>**  
**treprostинil**

EXTENDED-RELEASE TABLETS



**Unituxin<sup>®</sup>**  
(dinutuximab)  
Injection

# Tyvaso DPI is the Best Positioned Inhaled Prostacyclin



DOSING



TOLERABILITY




PARTICLE  
DEPOSITION



EASE OF USE



# Tyvaso DPI®: The first and only DPI device tailored for drug delivery to the distal lungs for PH<sup>1,2</sup>




1. Colleen McEvoy, et al. Tyvaso DPI: Drug-device characteristics and patient clinical considerations, *Pulmonary Pharmacology & Therapeutics*, Volume 83, 2023, 102266, ISSN 1094-5539, <https://doi.org/10.1016/j.pupt.2023.102266>. 2. Lung deposition is not solely affected by flow and resistance. Other factors including technique and particle size also influence it



# TETON-2: Overwhelmingly Positive Phase 3 Results for Idiopathic Pulmonary Fibrosis<sup>1,2</sup>

H-L<sup>3</sup> estimate: 95.6mL (95% CI, 52.2, 139.0) P<0.0001



## No. of Subjects


Inhaled Treprostinil	298	271	253	235	232	212	203
Placebo	295	259	255	251	238	226	212

1. The use of Tyvaso (inhaled treprostinil) for IPF is an investigational use and has not been approved by the FDA. 2. The TETON-2 study evaluated nebulized Tyvaso for the treatment of IPF 3. Hodges-Lehmann



# Ralinepag<sup>1</sup>: Potential *First and Only* Once-Daily Potent Prostacyclin Agonist

36.3m (p=0.004) mean 6MWD<sup>2</sup> increase from OLE<sup>3</sup> Baseline<sup>4</sup>



**ADVANCE  
OUTCOMES Data  
Expected Late  
1Q/Early 2Q  
2026<sup>5</sup>**


1. Ralinepag is not approved for pulmonary arterial hypertension or any other indication. 2. 6MWD = six-minute walk distance. 3. OLE = open label extension. 4. Barberà, et al. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension. *J. Adv Ther.* 2023. <https://doi.org/10.1007/s12325-023-02769-7>. 5. Timing is based on our discontinued enrollment and event accrual for the ADVANCE OUTCOMES study in 2025. Our expectations may change.




# Three Platforms for Creating an Unlimited Supply of Transplantable Organs



Xenotransplantation



Allogeneic  
Regenerative Medicine



Autologous  
Regenerative Medicine



# United Therapeutics: A Growth Story Unlike Any Other in Biotech

## PBC PHILOSOPHY

**When our patients succeed,** we all succeed

## FINANCIAL FOUNDATION

Unparalleled combination of **commercial execution** and **strong cash flow**

## STRATEGIC GROWTH PIPELINE

**Robust innovative pipeline** with potential to deliver **transformative growth**



# Q&A

## **Dr. Martine Rothblatt**


Chairperson & Chief Executive Officer

## **Michael Benkowitz**

President & Chief Operating Officer

## **James Edgemon**

Chief Financial Officer & Treasurer





A PUBLIC BENEFIT CORPORATION

